Long Focus Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-215,000
| Closed | -$195K | – | 101 |
|
|
2024
Q3 | $195K | Hold |
215,000
| – | – | 0.01% | 84 |
|
|
2024
Q2 | $214K | Hold |
215,000
| – | – | 0.01% | 85 |
|
|
2024
Q1 | $318K | Hold |
215,000
| – | – | 0.02% | 82 |
|
|
2023
Q4 | $234K | Hold |
215,000
| – | – | 0.01% | 93 |
|
|
2023
Q3 | $254K | Hold |
215,000
| – | – | 0.01% | 93 |
|
|
2023
Q2 | $303K | Hold |
215,000
| – | – | 0.01% | 90 |
|
|
2023
Q1 | $323K | Hold |
215,000
| – | – | 0.02% | 89 |
|
|
2022
Q4 | $252K | Hold |
215,000
| – | – | 0.02% | 89 |
|
|
2022
Q3 | $243K | Hold |
215,000
| – | – | 0.02% | 83 |
|
|
2022
Q2 | $340K | Hold |
215,000
| – | – | 0.04% | 89 |
|
|
2022
Q1 | $331K | Hold |
215,000
| – | – | 0.04% | 84 |
|
|
2021
Q4 | $527K | Buy |
+215,000
| New | +$527K | 0.07% | 76 |
|